Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
26 Juli 2023 - 2:30PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced that it will
report second quarter 2023 financial results on Wednesday, August
2, 2023, after the close of the market. The announcement will be
followed by a live audio webcast and conference call at 2:00 PM
Pacific Time/5:00 PM Eastern Time.
Listen-Only Webcast The listen-only webcast
will be made available on the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. A replay will be available on the Company's website
for approximately 30 days.
Conference Call Registration If you would like
the option to ask a question on the conference call, please use
this link to register. Upon registering for the conference call,
you will receive a personal PIN to access the call.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) products
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell candidates with the goal of delivering readily available
cell therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
Von Mai 2023 bis Mai 2024